Read by QxMD icon Read


David C Klonoff, Guido Freckmann, Lutz Heinemann
No abstract text is available yet for this article.
March 1, 2017: Journal of Diabetes Science and Technology
Anneka Freckmann, Monique Hines, Michelle Lincoln
PURPOSE: To investigate the face validity of a measure of therapeutic alliance for paediatric speech-language pathology and to determine whether a difference exists in therapeutic alliance reported by speech-language pathologists (SLPs) conducting face-to-face sessions, compared with telepractice SLPs or in their ratings of confidence with technology. METHOD: SLPs conducting telepractice (n = 14) or face-to-face therapy (n = 18) completed an online survey which included the Therapeutic Alliance Scales for Children - Revised (TASC-r) (Therapist Form) to rate clinicians' perceptions of rapport with up to three clients...
March 7, 2017: International Journal of Speech-language Pathology
Eric Renard
In an article in Journal of Diabetes Science and Technology, Freckmann et al report an evaluation of 2 infusion sets used for CSII in daily life, both from Roche. Because the 2 catheters differed at the soft cannula level in terms of geometry and introducer needle, focus was made on pain at insertion. While no significant difference was noted on this primary endpoint, unplanned catheter changes occurred in close to 20% of cases also with both catheter models, mainly driven by apparent insulin delivery issues...
March 2017: Journal of Diabetes Science and Technology
John Walsh, Guido Freckmann, Ruth Roberts, Lutz Heinemann
No abstract text is available yet for this article.
January 2017: Journal of Diabetes Science and Technology
Guido Freckmann, Annette Baumstark, Nina Jendrike, Delia Rittmeyer, Stefan Pleus, Cornelia Haug
BACKGROUND: Self-monitoring of blood glucose (BG) is an integral part in the therapy of people with diabetes, which is why blood glucose monitoring systems (BGMS) have to fulfill minimum accuracy requirements. However, accuracy is often assessed by trained operators, although such assessments do not necessarily allow for drawing conclusions on accuracy in the hands of lay users. METHODS: The accuracy of 4 different BGMS (Accu-Chek(®) Active, Accu-Chek(®) Performa, Contour(®)Plus, and OneTouch(®) SelectSimple™) in the hands of lay users and trained study personnel was assessed in this study...
April 2017: Diabetes Technology & Therapeutics
Rea M Lardelli, Ashleigh E Schaffer, Veerle R C Eggens, Maha S Zaki, Stephanie Grainger, Shashank Sathe, Eric L Van Nostrand, Zinayida Schlachetzki, Basak Rosti, Naiara Akizu, Eric Scott, Jennifer L Silhavy, Laura Dean Heckman, Rasim Ozgur Rosti, Esra Dikoglu, Anne Gregor, Alicia Guemez-Gamboa, Damir Musaev, Rohit Mande, Ari Widjaja, Tim L Shaw, Sebastian Markmiller, Isaac Marin-Valencia, Justin H Davies, Linda de Meirleir, Hulya Kayserili, Umut Altunoglu, Mary Louise Freckmann, Linda Warwick, David Chitayat, Susan Blaser, Ahmet Okay Çağlayan, Kaya Bilguvar, Huseyin Per, Christina Fagerberg, Henrik T Christesen, Maria Kibaek, Kimberly A Aldinger, David Manchester, Naomichi Matsumoto, Kazuhiro Muramatsu, Hirotomo Saitsu, Masaaki Shiina, Kazuhiro Ogata, Nicola Foulds, William B Dobyns, Neil C Chi, David Traver, Luigina Spaccini, Stefania Maria Bova, Stacey B Gabriel, Murat Gunel, Enza Maria Valente, Marie-Cecile Nassogne, Eric J Bennett, Gene W Yeo, Frank Baas, Jens Lykke-Andersen, Joseph G Gleeson
Deadenylases are best known for degrading the poly(A) tail during mRNA decay. The deadenylase family has expanded throughout evolution and, in mammals, consists of 12 Mg(2+)-dependent 3'-end RNases with substrate specificity that is mostly unknown. Pontocerebellar hypoplasia type 7 (PCH7) is a unique recessive syndrome characterized by neurodegeneration and ambiguous genitalia. We studied 12 human families with PCH7, uncovering biallelic, loss-of-function mutations in TOE1, which encodes an unconventional deadenylase...
March 2017: Nature Genetics
Lutz Heinemann, Diana Drossel, Guido Freckmann, Bernhard Kulzer
The estimation is that every third to fourth patient with diabetes suffers from some degree of diabetic retinopathy. Medical products for insulin administration (such as insulin pens and pumps) or glucose monitoring not optimized to the needs of these patients' represent a high barrier for optimal diabetes therapy in daily practice. To date, the number of devices suitable for visually impaired and blind patients with diabetes is scarce. This manuscript outlines the specific needs of this patient group with regard to systems for insulin administration, blood glucose measurement, and continuous glucose monitoring...
November 2016: Journal of Diabetes Science and Technology
Guido Freckmann, Stephan Arndt, Albrecht Fießelmann, Gerhard Klausmann, Kristina Pralle, Thomas Künsting, Bettina Petersen
BACKGROUND: Continuous subcutaneous insulin infusion (CSII) therapy is a valuable option especially for people with type 1 diabetes. Although insulin infusion sets (IIS) are essential components of most insulin pump systems, only few studies have been conducted on their performance and safety. In this study 2 IIS with soft cannulas were compared. METHODS: In an open-label, randomized, crossover, multicenter 8-week study 80 type 1 diabetic subjects on CSII (20-74 years, mean 46...
March 2017: Journal of Diabetes Science and Technology
Florian Reiterer, Philipp Polterauer, Michael Schoemaker, Guenther Schmelzeisen-Redecker, Guido Freckmann, Lutz Heinemann, Luigi Del Re
BACKGROUND: There is a need to assess the accuracy of continuous glucose monitoring (CGM) systems for several uses. Mean absolute relative difference (MARD) is the measure of choice for this. Unfortunately, it is frequently overlooked that MARD values computed with data acquired during clinical studies do not reflect the accuracy of the CGM system only, but are strongly influenced by the design of the study. Thus, published MARD values must be understood not as precise values but as indications with some uncertainty...
January 2017: Journal of Diabetes Science and Technology
Bernhard Gehr, Martin Holder, Bernhard Kulzer, Karin Lange, Andreas Liebl, Claudia Sahm, Simone von Sengbusch, Sandra Schlüter, Thorsten Siegmund, Ulrike Thurm, Ralph Ziegler, Guido Freckmann, Lutz Heinemann
BACKGROUND: Optimal usage of continuous glucose monitoring (CGM) requires adequate training of the users. Providing patients with a CGM system without such a training usually doesn't lead to the intended improvement in metabolic control. METHODS: In Germany we developed a structured training program ("SPECTRUM") to ensure a high quality standard for the use of CGM systems. RESULTS: This program is suitably for patients of all age groups and is applicable to all CGM systems and all forms of insulin therapy...
March 2017: Journal of Diabetes Science and Technology
Ralph Ziegler, Guido Freckmann, Lutz Heinemann
Giving a bolus is one major part in multiple dose insulin therapy (MDI) along with basal insulin substitution. To adjust the bolus optimally, different factors like carbohydrate content and composition of the meal, correction factors, and timing have to be considered. Advances in technologies like bolus advisors can assist the patients but still there a several open questions and technical challenges regarding boluses. This commentary provides an opportunity to address several of the above-mentioned factors influencing the result of bolusing...
January 2017: Journal of Diabetes Science and Technology
Michael Erbach, Guido Freckmann, Rolf Hinzmann, Bernhard Kulzer, Ralph Ziegler, Lutz Heinemann, Oliver Schnell
In general, patients with diabetes performing self-monitoring of blood glucose (SMBG) can strongly rely on the accuracy of measurement results. However, various factors such as application errors, extreme environmental conditions, extreme hematocrit values, or medication interferences may potentially falsify blood glucose readings. Incorrect blood glucose readings may lead to treatment errors, for example, incorrect insulin dosing. Therefore, the diabetes team as well as the patients should be well informed about limitations in blood glucose testing...
September 2016: Journal of Diabetes Science and Technology
Guido Freckmann, Stefan Pleus, Sandra Schlüter, Lutz Heinemann
No abstract text is available yet for this article.
May 2016: Diabetes Technology & Therapeutics
Stefan Pleus, Annette Baumstark, Delia Rittmeyer, Nina Jendrike, Cornelia Haug, Guido Freckmann
Objective For patients with diabetes, regular self-monitoring of blood glucose (SMBG) is essential to ensure adequate glycemic control. Therefore, accurate and reliable blood glucose measurements with SMBG systems are necessary. The international standard ISO 15197 describes requirements for SMBG systems, such as limits within which 95% of glucose results have to fall to reach acceptable system accuracy. The 2013 version of this standard sets higher demands, especially regarding system accuracy, than the currently still valid edition...
May 2016: Current Medical Research and Opinion
Emily J Todd, Kyle S Yau, Royston Ong, Jennie Slee, George McGillivray, Christopher P Barnett, Goknur Haliloglu, Beril Talim, Zuhal Akcoren, Ariana Kariminejad, Anita Cairns, Nigel F Clarke, Mary-Louise Freckmann, Norma B Romero, Denise Williams, Caroline A Sewry, Alison Colley, Monique M Ryan, Cathy Kiraly-Borri, Padma Sivadorai, Richard J N Allcock, David Beeson, Susan Maxwell, Mark R Davis, Nigel G Laing, Gianina Ravenscroft
BACKGROUND: Fetal akinesia/hypokinesia, arthrogryposis and severe congenital myopathies are heterogeneous conditions usually presenting before or at birth. Although numerous causative genes have been identified for each of these disease groups, in many cases a specific genetic diagnosis remains elusive. Due to the emergence of next generation sequencing, virtually the entire coding region of an individual's DNA can now be analysed through "whole" exome sequencing, enabling almost all known and novel disease genes to be investigated for disorders such as these...
November 17, 2015: Orphanet Journal of Rare Diseases
Peter Stephan, Christina Schmid, Guido Freckmann, Stefan Pleus, Cornelia Haug, Peter Müller
BACKGROUND: The measurement accuracy of systems for self-monitoring of blood glucose (SMBG) is usually analyzed by a method comparison in which the analysis results are displayed using difference plots or similar graphs. However, such plots become difficult to comprehend as the number of data points displayed increases. This article introduces a new approach, the rectangle target plot (RTP), which aims to provide a simplified and comprehensible visualization of accuracy data. METHODS: The RTP is based on ISO 15197 accuracy evaluations of SMBG systems...
October 9, 2015: Journal of Diabetes Science and Technology
Harald Kirchsteiger, Lutz Heinemann, Guido Freckmann, Volker Lodwig, Günther Schmelzeisen-Redeker, Michael Schoemaker, Luigi Del Re
BACKGROUND: The ongoing progress of continuous glucose monitoring (CGM) systems results in an increasing interest in comparing their performance, in particular in terms of accuracy, that is, matching CGM readings with reference values measured at the same time. Most often accuracy is evaluated by the mean absolute relative difference (MARD). It is frequently overseen that MARD does not only reflect accuracy, but also the study protocol and evaluation procedure, making a cross-study comparison problematic...
September 2015: Journal of Diabetes Science and Technology
Lutz Heinemann, Guido Freckmann
It remains to be seen as to what share of the market FGM will achieve if the manufacturer can supply any amount desired.Will a significant portion of the glucose monitoring market then be taken over by FGM? The availability of FGM as anew option for glucose monitoring can basically be evaluated positively and it does indeed clearly show the benefit of“more information” on the glucose trend. The relatively low price for glucose monitoring using FGM and the unusual market introduction (not first via the National Association of Statutory Health Insurance Funds, as was the case with CGM) have given increased attention to the use of more glucose information...
September 2015: Journal of Diabetes Science and Technology
Günther Schmelzeisen-Redeker, Michael Schoemaker, Harald Kirchsteiger, Guido Freckmann, Lutz Heinemann, Luigi Del Re
BACKGROUND: Continuous glucose monitoring (CGM) is a powerful tool to support the optimization of glucose control of patients with diabetes. However, CGM systems measure glucose in interstitial fluid but not in blood. Rapid changes in one compartment are not accompanied by similar changes in the other, but follow with some delay. Such time delays hamper detection of, for example, hypoglycemic events. Our aim is to discuss the causes and extent of time delays and approaches to compensate for these...
August 4, 2015: Journal of Diabetes Science and Technology
Guido Freckmann, Manuela Link, Christina Schmid, Stefan Pleus, Annette Baumstark, Cornelia Haug
BACKGROUND: Adherence to established standards (e.g., International Organization for Standardization [ISO] 15197) is important to ensure comparable and sufficient accuracy of systems for self-monitoring of blood glucose (SMBG). Accuracy evaluation was performed for different SMBG systems available in Europe with three reagent lots each. MATERIALS AND METHODS: Test procedures followed the recently published revision ISO 15197:2013. Comparison measurements were performed with a glucose oxidase (YSI 2300 STAT Plus™ glucose analyzer; YSI Inc...
September 2015: Diabetes Technology & Therapeutics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"